A randomized, double blind, placebo-controlled phase 1 study of DNL201 in healthy volunteer.
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2018
Price : $35 *
At a glance
- Drugs DNL-201 (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Denali Therapeutics Inc
- 08 Nov 2018 According to a Denali Therapeutics Inc media release, data were presented at the Michael J. Fox Foundation Parkinson's Disease Therapeutic Conference. The results met all endpoints.
- 01 Aug 2018 According to a Denali Therapeutics Inc media release, company has announced positive results of this trial.
- 26 Dec 2017 New trial record